Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. (NASDAQ: MGRX) is frequently in the news for developments across telemedicine-based wellness, digital assets, and capital markets activity. The company describes itself as focused on developing, marketing, and selling men’s and women’s health and wellness products and services via secure telemedicine platforms under the MangoRx and PeachesRx brands, and its announcements reflect this multi-faceted strategy.
News updates about Mangoceuticals often highlight new or expanded programs on its telehealth platforms, including offerings related to erectile dysfunction, hair growth, hormone replacement therapies, and weight management. The company has issued releases describing MangoRx Direct and PeachesRx Direct weight-management programs, as well as the launch of PeachesRx as a women’s telehealth brand focused initially on GLP-1–based weight management solutions.
Investors following MGRX news will also see coverage of Mangoceuticals’ work on MGX-0024, a patented antiviral compound described as a blend of natural polyphenols and zinc evaluated in poultry field studies for respiratory diseases. Additional headlines have addressed the company’s acquisition of intellectual property from Smokeless Technology Corp. related to stimulant and functional pouches, and prior announcements concerning exclusive rights to the plant-based nutraceutical Diabetinol, followed by a later filing describing the mutual rescission of that agreement.
Mangoceuticals’ news flow further includes updates on its Solana-focused digital asset treasury strategy through Mango DAT, LLC in partnership with Cube Group, as well as financing transactions such as private placements, registered direct offerings, warrant exercises, and equity line drawdowns. For readers tracking MGRX, this news page provides a centralized view of company-issued press releases and related market-moving disclosures. Bookmark this page to review new Mangoceuticals announcements, product and program descriptions, and SEC-reported events as they are released.
MangoRx, a men's health and wellness company, has announced the development of oral formulations of Semaglutide and Tirzepatide, branded as 'Slim' and 'Trim.' These drugs, traditionally available as injectables, are designed to aid in weight management. Clinical trials have shown impressive weight loss results, with Semaglutide yielding a 15.2% weight loss and Tirzepatide 15.7% over one year. The GLP-1 receptor agonists' market is projected to reach $164 billion by 2032. MangoRx's oral versions are expected to capture a significant market share due to patient preference for oral medications. The products will be available on MangoRx's telemedicine platform by Q3 2024, priced at $299/month for 'Slim' and $399/month for 'Trim.'
MangoRx (NASDAQ: MGRX) reported a 108% revenue growth in Q1 2024, increasing from $100,000 to $214,000 compared to Q1 2023. This growth is driven by strategic advances in customer acquisition, including the launch of a direct-to-clinic sales division. This allows medical professionals to prescribe MangoRx products directly, reducing customer acquisition costs. The company also acquired a global patent portfolio valued at $35 million for $20 million, aiming to launch non-pharmaceutical products starting with clinical trials in Q3 2024. MangoRx continues to expand its men's health and wellness product line, leveraging a unique telemedicine platform for seamless patient experience.
Mangoceuticals, Inc. (NASDAQ: MGRX) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. The company must reach a bid price of $1.00 per share for ten consecutive days to avoid delisting. Additionally, the 2024 Annual Meeting of Stockholders is scheduled for June 17, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.